Hector Banchs, MD
Cardiovascular Disease · Carolina, PRNPI 1467457929
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (47.4%), travel and lodging and food and beverage — rather than concentrated in one kind of arrangement. Boston Scientific accounts for 62.5% of it on its own, with 19 other manufacturers making up the rest. Among cardiovascular disease clinicians in PR with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 227 payments — averaging $178.85 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boston Scientific$25K
- Abbott$7K
- Johnson & Johnson$2K
- Lilly USA, LLC$2K
- Medtronic$2K
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$1K
- plus $1K from 14 others
Across 6 payments — averaging $2698.30 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly Export S.A. Puerto Rico Branch$15K
- Eli Lilly$2K
What the payments were for
- Consulting fees$3,4809%
- Speaking & faculty fees$19,23047%
- Travel & lodging$12,45731%
- Food & beverage$5,41813%
- Education$140%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boston Scientific | 30 | $25,361 |
| Abbott | 44 | $6,725 |
| Johnson & Johnson | 13 | $2,357 |
| Lilly USA, LLC | 3 | $1,980 |
| Medtronic(2 entities) | 28 | $1,839 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 74 | $1,020 |
| Johnson And Johnson International | 4 | $221 |
| Boehringer Ingelheim | 4 | $158 |
| Atricure, Inc. | 1 | $125 |
| AstraZeneca | 8 | $125 |
| Amgen | 1 | $119 |
| Actelion Pharmaceuticals US, Inc. | 1 | $118 |
| PBG Puerto Rico LLC | 6 | $110 |
| Biosense Webster, Inc. | 1 | $101 |
| Abiomed | 1 | $83 |
| E.r. Squibb & Sons, L.L.C. | 3 | $62 |
| Novartis | 2 | $33 |
| Biotronik Inc. | 1 | $24 |
| Merck | 1 | $22 |
| Bayer | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- GENERAL - THERAPIES$8,593
- S-ICD System Magnet$5,400
- EMBLEM MRI S-ICD$3,225
- AVEIR$2,922
- JARDIANCE$2,082
- XARELTO$2,080
- GENERAL TACHY$1,875
- ACCENT$1,400
- RESONATE EL ICD VR$1,350
- VIGILANT X4 CRT-D$1,350
- HeartMate 3 Left Ventricular Dev$1,185
- RESONATE$1,127
- GENERAL BRADY$900
- EMBLEM S ICD ELECTRODE DELIVERY SYSTEM$900
- AURORA EV-ICD MRI SURESCAN$680
- Micra$441
- Confirm Rx$161
- COBALT DR MRI SURESCAN$130
- ATRICLIP LAA EXCLUSION SYSTEM$125
- SYNERGY ABLATION SYSTEM$125
How this compares
$40,599 in reported general payments places this provider in the 95th percentile of 267 cardiovascular disease providers in Puerto Rico.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 472 | $527,571 |
| EntrestoSacubitril/Valsartan | 358 | $443,611 |
| JardianceEmpagliflozin | 250 | $275,367 |
| VyndamaxTafamidis | 11 | $251,386 |
| FarxigaDapagliflozin Propanediol | 143 | $156,837 |
| XareltoRivaroxaban | 115 | $143,088 |
| SynthroidLevothyroxine Sodium | 345 | $43,148 |
| Candesartan-HydrochlorothiazidCandesartan/Hydrochlorothiazid | 224 | $41,640 |
| Candesartan Cilexetil | 309 | $40,140 |
| SynjardyEmpagliflozin/Metformin Hcl | 49 | $36,728 |
| JanuviaSitagliptin Phosphate | 22 | $32,656 |
| BrilintaTicagrelor | 43 | $32,527 |
| MyforticMycophenolate Sodium | 44 | $31,916 |
| Repatha SureclickEvolocumab | 36 | $26,446 |
| JanumetSitagliptin Phos/Metformin Hcl | 28 | $25,079 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| NovartisEntresto | $33 | $443,611358 claims |
| Boehringer IngelheimJardiance, Synjardy, Tradjenta | $158 | $333,175318 claims |
| AstraZenecaFarxiga, Brilinta | $125 | $189,364186 claims |
| Johnson & JohnsonXarelto | $2,357 | $143,088115 claims |
| MerckJanuvia, Janumet | $22 | $57,73650 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 267 cardiovascular disease providers in Puerto Rico.
Other cardiovascular disease in Carolina
- Luis Renta RosaCarolina$83K
- Hector Mendez RiveraCarolina$10K
- Karen Rodriguez MaldonadoMayaguez$231K
- Jose NovoaBayamon$209K
- Manuel GuzmanSan Juan$203K
- Luis Rosado CarrilloGuaynabo$173K
- Jorge GonzalezCaguas$114K
- Luis GelyCaguas$89K
- Ramon PereaSan Juan$68K
- Denis Ruiz SerranoGuaynabo$66K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.